Core 1: Biospecimen and Translational Pathology Core

摘要：核心1 核心1负责采购、流动和交付给生物孢子调查员 标本(组织、肿瘤细胞、肿瘤浸润性免疫细胞和外周循环中的细胞)和 为所有参加临床试验的受试者提供临床病理注释。这是一个关键的 在标本处理、病理学和数据库操作方面需要不同专业知识的工作。为了这个 Reason，Core将由Whiteside博士共同指导，他将领导标本生物库工作，Dr。 卢卡斯是一名病理学家，他将领导注释工作。两名联席董事将由两名联席董事协助 调查人员：哈特曼博士，具有临床信息学系统方面的专业知识；卡鲁纳穆尔蒂博士， 具有黑色素瘤和皮肤癌专业知识的皮肤科医生。生物库和病理学核心是 嵌入免疫监测和细胞产品实验室(IMCPL)，这是一个共享的核心设施，位于 希尔曼癌症中心(Hillman癌症中心)，为先前的黑色素瘤和皮肤提供卓越的服务历史 匹兹堡癌症研究所(现为希尔曼癌症)的癌症孢子和癌症免疫治疗研究 中心)在过去的33年里。作为MSCP孢子的核心1，IMCPL将支持 以生物疗法为基础的所有项目的研究，在此之前对特定于项目的样本进行连续采集， 在治疗期间和治疗后进行干预。核心1号将获取并处理所有采集的体液和组织 来自参加孢子研究的黑色素瘤患者，并提供免疫病理组织评估， 包括使用Vectra Polaris多光谱对肿瘤浸润性免疫细胞进行多光谱分析 免疫荧光成像和纳米串GeoMx数字空间剖面图(DSP)。核心一号还将协助 孢子调查员在实施评估免疫应答所需的分析中的作用 治疗。CORE 1将确保它收集的所有样本都附有允许链接的注释 实验室分析与临床结果。数据和注释将存储在MSCP孢子研究中 数据库，并将根据既定的HIPAA协议为研究项目更新和检索。我们 与MSCP孢子调查人员有很长的合作历史，在这个孢子的背景下 计划，将完全致力于支持临床和翻译研究的患者 黑色素瘤或鳞状细胞癌。

Abstract: Core 1 Core 1 has the responsibility for the procurement, flow and delivery to the SPORE investigators of biological specimens (tissues, tumor cells, tumor-infiltrating immune cells and cells in the peripheral circulation) and for providing clinicopathological annotation for all subjects enrolled in the clinical trials. This is a critical responsibility that requires diverse expertise in specimen handling, pathology and data base operation. For this reason, the Core will be co-directed by Dr. Whiteside, who will lead the specimen biorepository efforts and Dr. Lucas, a pathologist, who will lead the annotation efforts. The two Co-Directors will be assisted by two Co- Investigators: Dr. Hartman with expertise in clinical informatics systems, and Dr. Karunamurthy, a dermatophatologist with expertise in melanoma and skin cancers. The Biorepository and Pathology Core is embedded in the Immunological Monitoring and Cell Products Laboratory (IMCPL), a shared core facility at the Hillman Cancer Center (HCC) with a history of distinguished service to the previous Melanoma and Skin Cancer SPORE and to cancer immunotherapy studies at the Pittsburgh Cancer Institute (now Hillman Cancer Center, HCC) over the past 33 years. In its role as Core 1 for the MSCP SPORE, the IMCPL will support the biotherapy-based research of all projects by performing project-specific serial accrual of specimens prior to, during and post therapeutic interventions. Core 1 will procure and process all body fluids and tissues harvested from melanoma patients enrolled in SPORE studies and provide immunopathological tissue evaluations, including multispectral analysis of tumor-infiltrating immune cells using Vectra Polaris multispectral immunofluorescence imaging and NanoString GeoMx Digital Spatial Profiling (DSP). Core 1 will also assist the SPORE investigators in implementing assays necessary for evaluation of immunologic responses to immune therapies. Core 1 will ensure that all samples it collects are accompanied by annotations that will permit linking laboratory analyses with clinical results. Data and annotations will be stored in the MSCP SPORE research database and will be updated and retrieved for research projects following established HIPAA protocols. We have a long history of collaboration with the MSCP SPORE investigators, and in the context of this SPORE Program, will be entirely dedicated to the support of the clinical and translational research in patients with melanoma or squamous cell carcinoma.